Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells - PubMed (original) (raw)
. 1993 Apr 1;150(7):2724-36.
Affiliations
- PMID: 8454852
Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells
N Shastri et al. J Immunol. 1993.
Abstract
Peptide fragments are displayed on the APC surface by MHC class I molecules as ligands for appropriate TCR. Sequence analysis of MHC-bound peptide mixtures has suggested that naturally processed peptides are defined by their length and by the presence of MHC allele-defined consensus motifs. To define the minimal OVA peptide presented by Kb MHC, and the requirements for generation of endogenous OVA/Kb complex, APC were transfected with OVA cDNA constructs. We show that optimal stimulation of OVA/Kb-specific B3Z T cell hybrid by Kb-APC requires the OVA257-264 peptide (SIINFEKL, SL8) whether added exogenously, or when synthesized endogenously as precursor polypeptides. Thus, all information necessary for expression of the OVA/Kb complex is contained within the Kb octapeptide motif shared by SL8. Unexpectedly, the SL8/Kb or the influenza NP/Db complexes were also generated in APC even when the peptide coding sequences were placed in incorrect translational reading frames. By contrast, identical manipulations of the translational reading frame of the lacZ reporter gene reduced protein synthesis to undetectable levels demonstrating the remarkable efficiency with which endogenous peptide/MHC are generated in and presented by APC to T cells. These characteristics of the endogenous presentation may explain how large numbers of distinct peptide/MHC complexes are displayed on the cell surface and surveyed by TCR.
Similar articles
- The role of MHC class I molecules in the generation of endogenous peptide/MHC complexes.
Malarkannan S, Goth S, Buchholz DR, Shastri N. Malarkannan S, et al. J Immunol. 1995 Jan 15;154(2):585-98. J Immunol. 1995. PMID: 7814870 - Bacterial antigen delivery systems: phagocytic processing of bacterial antigens for MHC-I and MHC-II presentation to T cells.
Svensson M, Pfeifer J, Stockinger B, Wick MJ. Svensson M, et al. Behring Inst Mitt. 1997 Feb;(98):197-211. Behring Inst Mitt. 1997. PMID: 9382741 Review. - Mechanism of tolerance induction.
Kruisbeek AM, Nieland JD, Jones LA. Kruisbeek AM, et al. Adv Exp Med Biol. 1992;323:101-9. doi: 10.1007/978-1-4615-3396-2_13. Adv Exp Med Biol. 1992. PMID: 1485558 Review. No abstract available.
Cited by
- A Chemical Approach to Assess the Impact of Post-translational Modification on MHC Peptide Binding and Effector Cell Engagement.
Kelly JJ, Bloodworth N, Shao Q, Shabanowitz J, Hunt D, Meiler J, Pires MM. Kelly JJ, et al. ACS Chem Biol. 2024 Sep 20;19(9):1991-2001. doi: 10.1021/acschembio.4c00312. Epub 2024 Aug 16. ACS Chem Biol. 2024. PMID: 39150956 Free PMC article. - The Lack of STING Impairs the MHC-I Dependent Antigen Presentation and JAK/STAT Signaling in Murine Macrophages.
Caiazza C, Brusco T, D'Alessio F, D'Agostino M, Avagliano A, Arcucci A, Ambrosino C, Fiume G, Mallardo M. Caiazza C, et al. Int J Mol Sci. 2022 Nov 17;23(22):14232. doi: 10.3390/ijms232214232. Int J Mol Sci. 2022. PMID: 36430709 Free PMC article. - Fibroblastic reticular cells mitigate acute GvHD via MHCII-dependent maintenance of regulatory T cells.
Shaikh H, Pezoldt J, Mokhtari Z, Gamboa Vargas J, Le DD, Peña Mosca J, Arellano Viera E, Kern MA, Graf C, Beyersdorf N, Lutz MB, Riedel A, Büttner-Herold M, Zernecke A, Einsele H, Saliba AE, Ludewig B, Huehn J, Beilhack A. Shaikh H, et al. JCI Insight. 2022 Nov 22;7(22):e154250. doi: 10.1172/jci.insight.154250. JCI Insight. 2022. PMID: 36227687 Free PMC article. - Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer.
Glorieux C, Xia X, You X, Wang Z, Han Y, Yang J, Noppe G, Meester C, Ling J, Robert A, Zhang H, Li SP, Wang H, Chiao PJ, Zhang L, Li X, Huang P. Glorieux C, et al. J Adv Res. 2022 Sep;40:109-124. doi: 10.1016/j.jare.2021.12.005. Epub 2021 Dec 21. J Adv Res. 2022. PMID: 36100320 Free PMC article. - Increasing Efficacy of Enveloped Whole-Virus Vaccines by In situ Immune-Complexing with the Natural Anti-Gal Antibody.
Galili U. Galili U. Med Res Arch. 2021 Jul;9(7):2481. doi: 10.18103/mra.v9i7.2481. Epub 2021 Jul 10. Med Res Arch. 2021. PMID: 34853815 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Research Materials
Miscellaneous